Abstract
Aldose reductase (AR) was cloned from the fungal pathogen, Magnaporthe grisea, expressed in Escherichia coli and purified to homogeneity. An experimental fungicide inhibits the M. grisea AR uncompetitively with respect to its aldehyde substrate with a Ki of 130 nM, the potency suggesting that AR is a biochemical target of the fungicide. The M. grisea AR has a high kcat and large differences in substrate specificities.
Keywords: fungal ALDOSE REDUCTASE, Magnaporthe grisea
Protein & Peptide Letters
Title: Inhibition of Fungal Aldose Reductase
Volume: 8 Issue: 5
Author(s): Ya-Jun Zheng, Yong Tao, Wei Zhang and Douglas B. Jordan
Affiliation:
Keywords: fungal ALDOSE REDUCTASE, Magnaporthe grisea
Abstract: Aldose reductase (AR) was cloned from the fungal pathogen, Magnaporthe grisea, expressed in Escherichia coli and purified to homogeneity. An experimental fungicide inhibits the M. grisea AR uncompetitively with respect to its aldehyde substrate with a Ki of 130 nM, the potency suggesting that AR is a biochemical target of the fungicide. The M. grisea AR has a high kcat and large differences in substrate specificities.
Export Options
About this article
Cite this article as:
Zheng Ya-Jun, Tao Yong, Zhang Wei and Jordan B. Douglas, Inhibition of Fungal Aldose Reductase, Protein & Peptide Letters 2001; 8 (5) . https://dx.doi.org/10.2174/0929866013409210
DOI https://dx.doi.org/10.2174/0929866013409210 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
Reviews on Recent Clinical Trials Current Update on Synopsis of miRNA Dysregulation in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders
Current Pharmaceutical Design Self-Care in Adults with Type 2 Diabetes Mellitus: A Systematic Review
Current Diabetes Reviews Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Current Pharmaceutical Biotechnology Antidotal Effects of Curcumin Against Agents-Induced Cardiovascular Toxicity
Cardiovascular & Hematological Disorders-Drug Targets Chemistry and Biology of Indoles and Indazoles: A Mini-Review
Mini-Reviews in Medicinal Chemistry The Future of Neuroregenerative Therapy for Parkinson’s Disease
Current Tissue Engineering (Discontinued) Can Environmentally Relevant Levels of Aluminium Promote the Onset and Progression of Neurodegenerative Diseases?
Current Inorganic Chemistry (Discontinued) Criteria for Creating and Assessing Mouse Models of Diabetic Neuropathy
Current Drug Targets Drug Targets from Genetics: Alpha-Synuclein
CNS & Neurological Disorders - Drug Targets Progress in the Research on Naturally Occurring Flavones and Flavonols: An Overview
Current Organic Chemistry Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Diagnosis, Pathogenesis and Therapeutic Targets in Amyotrophic Lateral Sclerosis
CNS & Neurological Disorders - Drug Targets The NOX1/4 Inhibitor GKT136901 as Selective and Direct Scavenger of Peroxynitrite
Current Medicinal Chemistry Does It Make Sense that Diabetes is Reciprocally Associated with Periodontal Disease?
Endocrine, Metabolic & Immune Disorders - Drug Targets Hypothalamic and Neuroendocrine Changes in Huntingtons Disease
Current Drug Targets Catechol-O-methyltransferase, Cognition and Alzheimer's Disease
Current Alzheimer Research